Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 8/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961236 | 0.88 | DDR1 (0.43) | DDR1CA12CA9AR | |
| SCHEMBL1661191 | 0.84 | DDR1 (0.35) | DDR1CA12CA9AR | |
| SCHEMBL1660964 | 0.84 | DDR1 (0.45) | DDR1CA12CA9AR | |
| SCHEMBL2389752 | 0.82 | CA12 (0.39) | DDR1CA12CA9AR | |
| SCHEMBL2389692 | 0.82 | CA12 (0.39) | DDR1CA12CA9AR | |
| SCHEMBL961805 | 0.82 | CA12 (0.39) | DDR1CA12CA9AR | |
| SCHEMBL1660345 | 0.81 | CA12 (0.38) | DDR1CA12CA9AR | |
| SCHEMBL1663166 | 0.80 | AR (0.36) | DDR1CA12CA9AR | |
| SCHEMBL14839979 | 0.80 | CA12 (0.37) | DDR1CA12CA9AR | |
| SCHEMBL957862 | 0.80 | AR (0.38) | DDR1CA12CA9AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012988-B2 | N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide | NOVARTIS AG (CH) | 2011-09-06 | — | — | US | disclosed |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | NOVARTIS AG | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | CYP3A7, CYP1A2, UGT1A7 | DDR1 2542/4885CA12 4097/4885CA9 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.